Appendix 4E - Preliminary Final Report
Filed with ASX · · 3 pages · English
Summary by 6ix AI
The report indicates a decrease in revenues from ordinary activities compared to the previous year, alongside an increase in losses attributable to the owners of the company. The company also reported a significant rise in research and development incentive income, reflecting successful initiatives in overseas R&D. Despite the losses, Optiscan Imaging Limited has advanced multiple R&D projects and introduced new medical imaging devices during the financial year.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Optiscan Imaging Limited on 6ix
Earlier from Optiscan Imaging
- Entitlement Issue Prospectus
- Optiscan Launches Entitlement Offer to Raise $17.75m
- Optiscan Initiates Breast Cancer Study in Melbourne
- Optiscan Signs Agreement with Long Grove Pharmaceuticals
- Optiscan Reveals InSpecta Device for Veterinary Medicine
Later from Optiscan Imaging
- Optiscan Partners with ACL to Advance Digital Pathology
- Optiscan Initiates Head & Neck Cancer Imaging Study
- Quarterly Activities/Appendix 4C Cash Flow Report
- Appendix 4D
- Optiscan Submits InSpecta FDA Dossier
Follow Optiscan Imaging into a list and get an email when it puts out news.
Follow Optiscan Imaging